Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
- Published on 05/06/2025
- Reading time: 5 min.
Li Yang 1, Ni Yunfeng 2, Lv Feng 2, Shi Yan 3, Chen Yedan 3, Wu Xiaoying 3, Pang Jiaohui 3, Huang Long 5,6, Shao Yang 3, Wang Tao 2, Min Jie 4, Song Yang 4
1 https://ror.org/02tbvhh96 Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Xi’an Jiaotong University Xi’an Shaanxi China
2 https://ror.org/04yvdan45 Department of Thoracic Surgery Tangdu Hospital, Fourth Military Medical University Xi’an Shaanxi China
3 Geneseeq Research Institute, Nanjing Geneseeq Technology Inc. Nanjing China
4 https://ror.org/04yvdan45 Department of Oncology Tangdu Hospital, Fourth Military Medical University Xi’an Shaanxi China
5 https://ror.org/01nxv5c88 Department of Lung Cancer Center The Second Affiliated Hospital of Nanchang University Nanchang China
6 https://ror.org/01nxv5c88 Department of Oncology The Second Affiliated Hospital of Nanchang University Nanchang China
Abstract
Background Epidermal growth factor receptor (EGFR) exon 19 insertions (19ins) represent a unique subclass of exon 19 alterations that has a relatively low frequency. Here, we aimed to elucidate the molecular characteristics and response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in lung cancer patients with EGFR 19ins.
Methods Next-generation sequencing was performed to profile the molecular characteristics of 83 non-small cell lung...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
